AbbVie attempting to rewrite US antitrust case over Humira, plaintiffs argue
MLex Summary: AbbVie's motion to dismiss US antitrust claims attempts to rewrite the complaint accusing it of entering into illegal agreements with pharmacy benefit managers to ensure that Humira would be...To view the full article, register now.
Already a subscriber? Click here to view full article